Analysis Article • Apr 29
Have your own idea? Try our Stock Screener
Japanese (NIKKEI) Biotech Industry Analysis
UpdatedMay 28, 2026
DataAggregated Company Financials
Companies35
- 7D3.1%
- 3M-16.1%
- 1Y-20.6%
- YTD-0.3%
Last week, the Biotech industry hasn't moved much but Oncolys BioPharma is up 56% in that time. Unfortunately though, the industry is down 19% over the past 12 months. Earnings are forecast to grow by 40% annually.
Industry Valuation and Performance
Has the Japanese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 28 May 2026 | JP¥1.1t | JP¥198.8b | -JP¥57,268,387,682.00 | 45x | -18.6x | 5.3x |
| Sat, 25 Apr 2026 | JP¥1.2t | JP¥202.7b | -JP¥49,271,096,682.00 | 61.5x | -23.5x | 5.7x |
| Mon, 23 Mar 2026 | JP¥1.1t | JP¥202.7b | -JP¥49,460,645,682.00 | 58x | -22.7x | 5.5x |
| Wed, 18 Feb 2026 | JP¥1.2t | JP¥200.5b | -JP¥49,329,029,682.00 | 324.6x | -24.1x | 5.9x |
| Fri, 16 Jan 2026 | JP¥1.1t | JP¥198.7b | -JP¥70,727,387,000.00 | 62x | -15.8x | 5.6x |
| Sun, 14 Dec 2025 | JP¥991.4b | JP¥197.4b | -JP¥71,614,409,000.00 | 37x | -13.8x | 5x |
| Tue, 11 Nov 2025 | JP¥1.1t | JP¥197.7b | -JP¥63,181,000,000.00 | 63.6x | -17.1x | 5.5x |
| Thu, 09 Oct 2025 | JP¥1.2t | JP¥197.7b | -JP¥65,794,561,000.00 | 63.4x | -18.1x | 6x |
| Sat, 06 Sep 2025 | JP¥1.2t | JP¥193.5b | -JP¥68,135,862,000.00 | 123.8x | -17.3x | 6.1x |
| Mon, 04 Aug 2025 | JP¥1.2t | JP¥218.1b | -JP¥46,563,403,000.00 | 109.7x | -25x | 5.3x |
| Wed, 02 Jul 2025 | JP¥1.1t | JP¥218.2b | -JP¥43,672,020,000.00 | 95.5x | -25.6x | 5.1x |
| Fri, 30 May 2025 | JP¥1.2t | JP¥214.8b | -JP¥40,595,949,000.00 | 14.8x | -29.6x | 5.6x |
| Sun, 27 Apr 2025 | JP¥1.0t | JP¥207.8b | -JP¥39,029,205,000.00 | 14.8x | -26.6x | 5x |
| Tue, 25 Mar 2025 | JP¥1.0t | JP¥207.8b | -JP¥39,285,917,000.00 | 15.8x | -26.2x | 5x |
| Thu, 20 Feb 2025 | JP¥1.1t | JP¥207.4b | -JP¥38,725,547,000.00 | 16.1x | -28x | 5.2x |
| Sat, 18 Jan 2025 | JP¥995.1b | JP¥207.3b | -JP¥13,514,081,000.00 | 20.1x | -73.6x | 4.8x |
| Mon, 16 Dec 2024 | JP¥1.1t | JP¥206.4b | -JP¥11,970,899,000.00 | 21.2x | -88.6x | 5.1x |
| Wed, 13 Nov 2024 | JP¥1.1t | JP¥215.7b | -JP¥6,488,528,000.00 | 22.9x | -170.9x | 5.1x |
| Fri, 11 Oct 2024 | JP¥1.1t | JP¥214.3b | -JP¥2,078,229,000.00 | 21.1x | -531.2x | 5.2x |
| Sun, 08 Sep 2024 | JP¥1.0t | JP¥210.1b | -JP¥469,229,000.00 | 15.5x | -2198.7x | 4.9x |
| Tue, 06 Aug 2024 | JP¥834.2b | JP¥187.5b | -JP¥16,096,875,000.00 | 47.4x | -51.8x | 4.4x |
| Thu, 04 Jul 2024 | JP¥998.6b | JP¥187.7b | -JP¥15,773,284,000.00 | 90.3x | -63.3x | 5.3x |
| Sat, 01 Jun 2024 | JP¥807.5b | JP¥195.7b | -JP¥14,113,087,000.00 | 93.9x | -57.2x | 4.1x |
| Mon, 29 Apr 2024 | JP¥753.2b | JP¥198.9b | -JP¥14,917,877,000.00 | 42.4x | -50.5x | 3.8x |
| Wed, 27 Mar 2024 | JP¥756.2b | JP¥194.2b | -JP¥15,457,633,000.00 | 60.3x | -48.9x | 3.9x |
| Fri, 23 Feb 2024 | JP¥807.8b | JP¥196.2b | -JP¥18,778,997,000.00 | 65.3x | -43x | 4.1x |
| Sun, 21 Jan 2024 | JP¥781.8b | JP¥222.3b | -JP¥12,604,827,000.00 | 17.1x | -62x | 3.5x |
| Tue, 19 Dec 2023 | JP¥748.3b | JP¥224.2b | -JP¥12,970,409,000.00 | 16.9x | -57.7x | 3.3x |
| Thu, 16 Nov 2023 | JP¥753.1b | JP¥220.9b | -JP¥8,936,128,000.00 | 16.8x | -84.3x | 3.4x |
| Sat, 14 Oct 2023 | JP¥787.0b | JP¥223.0b | -JP¥14,518,735,000.00 | 22.7x | -54.2x | 3.5x |
| Mon, 11 Sep 2023 | JP¥893.3b | JP¥225.4b | -JP¥19,581,085,000.00 | 45.7x | -45.6x | 4x |
| Wed, 09 Aug 2023 | JP¥883.3b | JP¥223.7b | -JP¥20,858,086,000.00 | 50.4x | -42.3x | 3.9x |
| Fri, 07 Jul 2023 | JP¥944.3b | JP¥223.0b | -JP¥19,224,671,000.00 | 56.4x | -49.1x | 4.2x |
| Sun, 04 Jun 2023 | JP¥955.1b | JP¥218.4b | -JP¥25,404,671,000.00 | 37.6x | -37.6x | 4.4x |
Price to Earnings Ratio
-37.6x
Current Industry PE
- Investors are optimistic on the Japanese Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 4.8x is lower than the industry's current PS ratio of 5.4x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Revenues have also declined 3.1% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the Japanese Healthcare industry?
| JP Market | 3.59% | |
| Healthcare | -0.24% | |
| Biotech | 3.11% | |
| Biotech | 3.11% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 4588 Oncolys BioPharma | JP¥3.08k | 33.9% +JP¥22.8b | 411.6% | PS3154.6x | |
| 7774 Japan Tissue Engineering | JP¥627.00 | 8.3% +JP¥1.9b | 7.2% | PS11.7x | |
| 4593 Healios K.K | JP¥331.00 | 3.4% +JP¥1.5b | -11.7% | PS603.9x | |
| 219A Heartseed | JP¥1.60k | 3.4% +JP¥1.2b | -41.4% | PE61.7x | |
| 4564 OncoTherapy Science | JP¥21.00 | 5.0% +JP¥383.6m | -4.5% | PS10x |